Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 3,900 trials

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Richter Transformation: Testing New Combination Therapy

We are studying a combination of three medications for patients with Richter transformation of chronic lymphocytic leukemia. The goal is to evaluate how well this treatment works and its safety.

Chronic Lymphocytic Leukaemia Variants>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Choroidal Melanoma: Belzupacap Sarotalocan Treatment

We are studying a new treatment for people with primary indeterminate lesions or small choroidal melanoma. The goal is to see if it is more effective and safe compared to a placebo.

Choroidal Melanoma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncologyOphthalmology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Hydroxychloroquine for Pregnancy Outcomes in Women with Antiphospholipid Antibodies

We are studying whether hydroxychloroquine can improve pregnancy outcomes for women with antiphospholipid antibodies. This research aims to help understand its potential benefits during pregnancy.

Antiphospholipid Antibodies>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesGynecology and ObstetricsInternal Medicine

Vitamin D Deficiency: Cholecalciferol Study for Postmenopausal Women

We are investigating the right dose of Cholecalciferol to help postmenopausal women with vitamin D deficiency. The study also looks at how satisfied participants are with this vitamin D supplement.

Postmenopausal Women6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Myeloma: ABBV-383 Treatment Study

We are evaluating the safety and optimal dosing of ABBV-383 for individuals with relapsed or refractory multiple myeloma. This study aims to improve treatment options for this challenging condition.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Oncology

Post-Stroke Pain: Understanding Nerve Roles

We are investigating how peripheral nerves influence pain in individuals who have had a stroke. This research may help develop better pain management strategies for stroke survivors.

Central Neuropathic Pain After Stroke>2 yearsConfirmation phase (III)Neurology

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Prostate Cancer: Estradiol and Exercise Study

We are exploring whether transdermal estradiol and resistance training can help reduce side effects like sexual dysfunction in men undergoing androgen deprivation therapy for prostate cancer. The study also looks at safety and quality of life improvements.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyUrology

Cytisine for Quitting Nicotine in E-Cigarettes and Tobacco

We are studying whether cytisine, combined with behavioral support, helps people quit using nicotine in e-cigarettes or tobacco cigarettes better than a placebo. This trial is for individuals motivated to stop using these products.

Quitting Electronic Cigarettes≤3 monthsConfirmation phase (III)Standard MedicinesPsychiatry

Advanced Solid Tumors: RO7502175 Treatment Study

We are evaluating a new treatment for patients with locally advanced or metastatic solid tumors. The study looks at its safety and effectiveness alone and with another cancer therapy.

Locally Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Myelofibrosis: Navtemadlin with Ruxolitinib

We are studying whether adding navtemadlin to ruxolitinib helps patients with myelofibrosis who aren't responding well to their current treatment. The trial looks at changes in spleen size and symptoms, along with safety and survival.

MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Insomnia in Psychiatric Patients: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep and overall well-being in patients with psychiatric disorders and chronic insomnia. This trial compares these treatments to a placebo to find the most effective option.

Psychiatric Disorders and Insomnia>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPsychiatry

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine